What is Aarti Drugs Ltd (AARTIDRUGS) share price return in the past 10 years?

Aarti Drugs Ltd share price has appreciated 12.7% annually (CAGR) over the past ten years.

What is the share price of Aarti Drugs Ltd (AARTIDRUGS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Aarti Drugs Ltd (AARTIDRUGS) on 05-Jun-2026 16:59:59 at 16:59 is 377.10.

What is the P/E ratio of Aarti Drugs?

The latest standalone P/E ratio of Aarti Drugs as of 05-Jun-2026 is 20.23.

What is the P/B ratio of Aarti Drugs Ltd (AARTIDRUGS)?

The latest standalone P/B ratio of Aarti Drugs Ltd (AARTIDRUGS) as of 05-Jun-2026 is 2.44.

What is the 52-week high and low of Aarti Drugs Ltd (AARTIDRUGS)?

The 52-week high of Aarti Drugs Ltd (AARTIDRUGS) is Rs. 574.95 and the 52-week low is Rs. 318.60.

Aarti Drugs Ltd (AARTIDRUGS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Aarti Drugs Ltd (AARTIDRUGS)
Brand: Aarti Drugs

Aarti Drugs Ltd (AARTIDRUGS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524348 NSE: AARTIDRUGS Pharmaceuticals & Drugs | Small Cap | Aarti Drugs Share Price

Aarti Drugs Ltd (AARTIDRUGS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524348 NSE: AARTIDRUGS Pharmaceuticals & Drugs | Small Cap | Aarti Drugs Share Price

Key Metrics

Valuation Multiples

Market Cap

₹3,423 Cr.

Current Price

₹377.1

52-Week Low / High

₹319 / 575

TTM EPS

₹21.4

TTM Sales

₹2,565 Cr.

Book Value per Share

₹169.7

P/E Ratio

17.56

Lower than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

2.21

Lower than its 5-year historical median

Price to Sales (P/S)

1.33

Lower than its 5-year historical median

EV/EBITDA

12.80

Lower than its 5-year historical median

Dividend Yield

0.29%

Profitability Efficiency

Return on Equity (ROE)

12.68%

Outperforms industry median

Return on Capital Employed (ROCE)

13.11%

Outperforms industry median

Return on Assets (ROA)

6.71%

Operating Profit Margin

12.2%

Net Profit Margin

7.04%

Gross Profit Margin

11.2%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-5.6%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-9.54%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

-2.03%

Asset Quality

Promoter Holding

55.03%

Pledged shares (%) of Promoter's holding (%)

2.47%

Reserves

₹1,458 Cr.

Equity

₹91.3 Cr.

Face Value

₹10

All Time Low / High

₹0.57 / 1025.00

Aarti Drugs stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Undervalued

Check Valuation charts

Price Trend

Semi Strong

Check Price chart

Q.1 Is Aarti Drugs Ltd a good quality company?

Aarti Drugs Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Aarti Drugs Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Aarti Drugs Ltd vs industry peers?

Aarti Drugs Ltd revenue CAGR is 5.74%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Aarti Drugs Ltd?

Promoters hold 55.03% of the Aarti Drugs Ltd, with 2.47% of their stake pledged, indicating low pledge risk.

Q.1 Stock return of Aarti Drugs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 12.1% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	18%	18.1%	17.3%	17%	21.4%	34.5%	20.8%	15.5%	15%	13.1%	-
Value Creation Index ⓘ	0.3	0.3	0.2	0.2	0.5	1.6	0.5	0.1	0.1	-0.1	-
Growth Parameters ⓘ
Sales ⓘ	1,140	1,195	1,244	1,561	1,806	2,155	2,489	2,716	2,529	2,387	2,565
Sales YoY Gr.	-	4.9%	4.1%	25.5%	15.7%	19.3%	15.5%	9.1%	-6.9%	-5.6%	-
Adj EPS ⓘ	7.1	8.6	8.7	9.2	14.8	29.8	22.1	18	18.7	18.4	21.4
YoY Gr.	-	20.7%	2%	5.8%	60.6%	101.1%	-25.8%	-18.9%	4%	-1.4%	-
BVPS (₹) ⓘ	36.9	41.9	48.3	57.6	70	98	111.9	128.8	139.4	150	169.7
Adj Net Profit ⓘ	68.7	81.7	82.3	87.1	138	278	205	166	172	168	195
Cash Flow from Ops. ⓘ	133	175	69.8	143	251	155	70.4	133	359	245	-
Debt/CF from Ops. ⓘ	3.6	2.7	7.8	3.5	1.5	2.2	7.7	4.6	1.6	2.5	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8.6%	5.7%	-1.4%	-5.6%
Adj EPS ⓘ	11.2%	4.4%	-6%	-1.4%
BVPSⓘ	16.9%	16.5%	10.3%	7.6%
Share Price	12.7%	-13.1%	-6.4%	-18.4%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	20.7	21.6	19.2	17.4	23.1	35.5	21	14.9	13.9	12.7	13.4
Op. Profit Mgn % ⓘ	15.8	16.1	16.2	13.5	14.7	20.4	13.4	11.4	12.7	12.2	12.1
Net Profit Mgn % ⓘ	6	6.8	6.6	5.6	7.7	12.9	8.2	6.1	6.8	7	7.6
Debt to Equity ⓘ	1.4	1.2	1.2	0.9	0.6	0.4	0.5	0.5	0.4	0.5	0.2
Working Cap Days ⓘ	162	162	191	178	169	165	180	195	205	205	91
Cash Conv. Cycle ⓘ	81	76	94	91	89	82	99	107	112	112	35

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	1,140	1,195	1,244	1,561	1,806	2,155	2,489	2,716	2,529	2,387
Operating Expenses ⓘ +	960	1,005	1,042	1,350	1,541	1,714	2,156	2,407	2,208	2,097
Manufacturing Costs	142	164	201	227	264	280	359	398	407	411
Material Costs	735	744	738	1,014	1,127	1,263	1,614	1,814	1,605	1,467
Employee Cost	40	48	52	55	61	66	69	80	91	100
Other Costs ⓘ	43	48	50	55	88	106	113	115	105	119
Operating Profit ⓘ	180	190	202	211	266	440	333	309	321	290
Operating Profit Margin (%)	15.8%	15.9%	16.2%	13.5%	14.7%	20.4%	13.4%	11.4%	12.7%	12.2%
Other Income ⓘ +	0	4	1	2	1	5	11	2	4	16
Exceptional Items ⓘ	0	0	0	4	4	0	0	0	0	0
Interest ⓘ	48	40	38	44	37	26	24	37	38	39
Depreciation ⓘ	37	38	40	43	49	50	50	50	51	56
Profit Before Tax ⓘ	95	116	125	131	185	369	270	224	236	212
Tax ⓘ	27	34	42	41	44	89	65	58	64	44
Profit After Tax	69	82	82	90	141	280	205	166	172	168
PAT Margin (%)	6.0%	6.8%	6.6%	5.8%	7.8%	13.0%	8.2%	6.1%	6.8%	7.0%
Adjusted EPS (₹)	7.1	8.6	8.7	9.5	15.2	30.1	22.1	18.0	18.7	18.4
Dividend Payout Ratio (%)	23.80%	2.90%	2.90%	2.60%	3.30%	8.30%	4.50%	5.60%	5.40%	5.40%

Valuation of Aarti Drugs - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	357	400	455	543	652	913	1,036	1,192	1,282	1,369
Share Capital ⓘ	24	24	24	24	23	93	93	93	92	91
Reserves ⓘ	333	376	432	520	629	820	944	1,100	1,190	1,278
Debt +	450	446	508	471	338	305	495	565	490	556
Long Term Debt	191	202	203	208	180	148	138	205	275	284
Short Term Debt	258	245	306	263	158	157	356	361	215	272
Minority Interest	0	0	0	0	-0	-0	-0	0	0	0
Trade Payables	185	197	259	243	330	330	469	480	425	416
Others Liabilities ⓘ	110	148	167	198	256	218	208	183	235	233
Total Liabilities ⓘ	1,102	1,191	1,389	1,455	1,577	1,766	2,208	2,421	2,432	2,575
Fixed Assets
Net Fixed Assets ⓘ +	493	581	602	625	644	665	690	676	811	866
Gross Block	725	848	909	970	1,031	1,101	1,169	1,202	1,388	1,496
Accumulated Depreciation	232	267	307	345	387	436	479	526	577	630
CWIP ⓘ	34	14	28	33	12	19	77	210	261	330
Investments ⓘ	5	12	11	12	13	17	19	19	20	22
Inventories	178	210	278	247	325	415	526	516	486	473
Trade Receivables	332	297	375	459	489	555	750	865	705	751
Cash Equivalents	5	4	4	6	8	10	22	9	9	8
Others Assets ⓘ	55	73	90	75	85	84	124	126	141	124
Total Assets ⓘ	1,102	1,191	1,389	1,455	1,577	1,766	2,208	2,421	2,432	2,575

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	133	175	70	143	251	155	70	133	359	245
PBT ⓘ	95	116	125	131	185	369	270	224	236	212
Adjustment ⓘ	79	72	75	75	87	69	71	85	83	84
Changes in Working Capital ⓘ	-21	8	-105	-33	19	-186	-187	-116	103	4
Tax Paid ⓘ	-20	-21	-25	-30	-41	-97	-83	-60	-62	-55
Cash Flow From Investing Activity ⓘ +	-99	-107	-74	-62	-33	-72	-150	-164	-224	-165
Capex	-100	-107	-75	-63	-37	-77	-152	-165	-226	-177
Net Investments	-0	-0	0	0	3	0	0	0	0	0
Others ⓘ	1	1	1	1	1	6	2	1	2	12
Cash Flow From Financing Activity ⓘ +	-33	-68	4	-80	-215	-81	92	17	-136	-82
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	1	0	0
Net Proceeds from Borrowing ⓘ	28	9	5	3	-21	-34	-7	60	102	-7
Interest Paid ⓘ	-44	-36	-35	-40	-34	-23	-21	-36	-31	-33
Dividend Paid ⓘ	-24	0	-2	-2	-7	-23	-10	-9	-9	-9
Others ⓘ	6	-41	36	-41	-153	-1	129	1	-198	-32
Net Cash Flow ⓘ	1	-0	0	1	2	2	13	-14	-1	-2

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	20.65	21.6	19.24	17.97	23.65	35.81	21.03	14.93	13.87	12.68
ROCE (%)	17.95	18.14	17.31	17.01	21.39	34.52	20.75	15.49	15.01	13.11
Asset Turnover Ratio	1.17	1.12	0.98	1.1	1.19	1.29	1.25	1.17	1.04	0.95
PAT to CFO Conversion(x)	1.93	2.13	0.85	1.59	1.78	0.55	0.34	0.8	2.09	1.46
Working Capital Days
Receivable Days	95.60	89.10	97.10	97.50	95.70	88.40	95.70	108.50	113.30	111.30
Inventory Days	50.70	55	70.50	61.40	57.80	62.70	69	70	72.30	73.30
Payable Days	87.30	93.60	112.70	90.30	92.60	95.30	90.30	95.50	103	104.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

2.47

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Aarti Drugs Ltd FAQs

The current trading price of Aarti Drugs on 05-Jun-2026 16:59 is ₹377.1.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Aarti Drugs stood at ₹3,423.1 Cr

The latest P/E ratio of Aarti Drugs as of 04-Jun-2026 is 20.23.

The latest P/B ratio of Aarti Drugs as of 04-Jun-2026 is 2.44.

The 52-week high of Aarti Drugs is ₹575.0 and the 52-week low is ₹318.6.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aarti Drugs is ₹2,260 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Aarti Drugs Ltd is a good quality company.

The key valuation ratios of Aarti Drugs Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Aarti Drugs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Aarti Drugs Ltd

Aarti Drugs Ltd. was established in the year 1984 and forms part of $900 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations.

Over the years, the Company has been able to carve a niche for itself and is looking forward to expand the volumes. With the government initiative to encourage private health insurance schemes, consumer spending on medicines is expected to increase, which will spur growth in the generic sector in the domestic market.

The manufacturing-units of Aarti Drugs Ltd. are GMP certified. The Company is also in the process of acquiring an ISO 9002 compliance for all its units and one of the units has already been approved.

The Company aims at becoming the first choice of this expanding market through better products, ensuring quality and timely delivery.

Business area of the company

The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited.

Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

Awards and accolades

1991-1992: Outstanding Performance in Export from Chemexcil
2001: Best Vendor from Organization of Pharmaceutical Product
2005: Customer Responsiveness from Avaya Global Connect
2013: Business Partner of the year from Abbott
2014: Appreciation as business partner from Abbott
2014: Certificate of Recognition - Star Export House from Government of India (Ministry of Commerce and Industry)
2015: Business Partner of the year from Abbott
2006: Customer Responsiveness from Avaya Global Connect
2016: Business Partner of the year from Abbott
2016: Outstanding Performance in Export from Pharmexcil
2017: Business Partner of the year from Abbott
2017: Outstanding Performance Latin American Export from Pharmexcil
2018: Business Partner of the year from Abbott

Milestones

1984: Incorporation
1993: Listed On BSE Limited
1996: Amalgamation of Rupal Chemical Industries Limited, Rashesh Chemicals & Pharmaceuticals Limited, Manjarati Chemicals Private Limited, Manjarati Plastisizer Private Limited, Effective Chemicals Private Limited, Star Aluminium Industries Limited and Avez Wire
1998: Turnover of Rs 100 crore
2003: Listed On National Stock Exchange of India Limited
2008: Approval of USFDA Plant
2011: Turnover of Rs 500 crore
2014: Turnover of Rs 1000 crore 100% holdings in Pinnacle Life Science Pvt. Ltd.
2015: Aarti Drugs Limited -PBT More than Rs 100 crore
2017: Rs 100 crore Turnover Pinnacle Life Science Pvt. Ltd. Pinnacle Life Science (Sikkim) Plant ready for operations
2019: Turnover of Rs 1500 crore
2020: Crossed Rs 2000 crore consolidated turnover and Rs 200 crore formulation turnover
2020: Crossed PAT amounted Rs 200 crore
2022: Consolidated revenue Rs 2500 crore

Aarti Drugs Ltd (AARTIDRUGS)

Aarti Drugs Ltd (AARTIDRUGS)

Aarti Drugs stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Aarti Drugs - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Aarti Drugs Ltd FAQs

About Aarti Drugs Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Aarti Drugs Ltd (AARTIDRUGS)

Aarti Drugs Ltd (AARTIDRUGS)

Aarti Drugs stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Aarti Drugs - Consolidated

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Aarti Drugs Ltd FAQs

What is the share price of Aarti Drugs?

What is the market cap of Aarti Drugs?

What is the P/E ratio of Aarti Drugs?

What is the P/B ratio of Aarti Drugs?

What is the 52-week high and low of Aarti Drugs?

What is the TTM revenue of Aarti Drugs?

Is Aarti Drugs Ltd a good quality company?

Is Aarti Drugs Ltd undervalued or overvalued?

Is Aarti Drugs Ltd a good buy now?

About Aarti Drugs Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.